These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 31910303

  • 1. Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes.
    Libianto R, Davis TM, Ekinci EI.
    Med J Aust; 2020 Feb; 212(3):133-139. PubMed ID: 31910303
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS.
    Circulation; 2019 Apr 23; 139(17):2022-2031. PubMed ID: 30786725
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Not Available].
    Toft E, Rydén M.
    Lakartidningen; 2018 Feb 20; 115():. PubMed ID: 29461566
    [Abstract] [Full Text] [Related]

  • 8. Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients.
    Anderson S, Cotiguala L, Tischer S, Park JM, McMurry K.
    Ann Pharmacother; 2021 Apr 20; 55(4):496-508. PubMed ID: 32795145
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
    Dhindsa DS, Mehta A, Sandesara PB, Thobani A, Brandt S, Sperling LS.
    Curr Cardiol Rep; 2019 Jul 27; 21(9):100. PubMed ID: 31352613
    [Abstract] [Full Text] [Related]

  • 11. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors.
    Secrest MH, Udell JA, Filion KB.
    Trends Cardiovasc Med; 2017 Apr 27; 27(3):194-202. PubMed ID: 28291655
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis.
    Kadowaki T, Yamamoto F, Taneda Y, Naito Y, Clark D, Lund SS, Okamura T, Kaku K.
    Expert Opin Drug Saf; 2021 Jun 27; 20(6):707-720. PubMed ID: 33706621
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Treatment of Diabetes in Patients with Heart Failure.
    Bowes CD, Lien LF, Butler J.
    Curr Cardiol Rep; 2018 Aug 27; 20(10):97. PubMed ID: 30151728
    [Abstract] [Full Text] [Related]

  • 17. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.
    Nassif ME, Kosiborod M.
    Am J Cardiol; 2019 Dec 15; 124 Suppl 1():S12-S19. PubMed ID: 31741435
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus-Part 1.
    Yandrapalli S, Jolly G, Horblitt A, Pemmasani G, Sanaani A, Aronow WS, Frishman WH.
    Cardiol Rev; 2020 Dec 15; 28(4):177-189. PubMed ID: 32282393
    [Abstract] [Full Text] [Related]

  • 20. A Review on the Effects of New Anti-Diabetic Drugs on Platelet Function.
    Yaribeygi H, Atkin SL, Jamialahmadi T, Sahebkar A.
    Endocr Metab Immune Disord Drug Targets; 2020 Dec 15; 20(3):328-334. PubMed ID: 31612835
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.